Pyrrolidine, 2-2-(1R)-1-(4-Chlorophenyl)-1-Phenylethoxyethyl-1-Methyl-, (2R)-

Content Uniformity and Process Control for 0.5–1.0% w/w Clemastine Base in Tablet Blends

When (2R)-2-[2-((1R)-1-(4-chlorophenyl)-1-phenylethoxy)ethyl]-1-methylpyrrolidine (cleastine base) is intended for oral solid dosage forms delivering 1 mg or 0.5 mg of active per unit, the primary manufacturing risk is content uniformity failure due to the extremely low drug load — often 0.5–0.67% w/w of the total core weight. The base is typically converted in situ to clemastine fumarate prior to granulation by wet-massing with a stoichiometric amount of fumaric acid in an isopropanol-water cosolvent at 40–45 °C, a step that simultaneously improves blend uniformity by coating the API onto microcrystalline cellulose seed particles. Compliance with USP〈905〉 Uniformity of Dosage Units and the USP Clemastine Fumarate monograph mandates that assay values for individual tablets fall within 95.0–105.0% and that total related substances do not exceed 2.0%, with any individual unspecified impurity limited to 0.5%; enantiomeric purity is governed by a specific chiral HPLC procedure described in the monograph, requiring non-therapeutic (2S)-enantiomer and diastereomers to remain below 1.0% total. During high-shear wet granulation (bowl mixer with bottom drive, impeller tip speed 4–8 m/s, chopper 1 500–3 000 rpm), the particle size distribution of the clemastine base input must be tightly controlled — laser diffraction data consistently show that batches with d₉₀ exceeding 15 µm generate out-of-specification content uniformity values in the first compression trials, whereas a milled input with d₅₀ ≤ 5 µm and d₉₀ ≤ 10 µm achieves acceptance value (AV) below 10.0 across all speed tiers of a rotary press (e.g., 36-station machine at 80 000 tph). Granulation endpoint moisture, determined by loss-on-drying at 85°C, must be kept below 2.5 % w/w because residual free water above 3.0 % has been correlated with a measurable increase in the 4-chlorobenzophenone-related hydrolytic impurity under accelerated conditions at 40 °C/75 % RH. The lubricant blending step is particularly sensitive: extended mixing of magnesium stearate beyond 5 minutes at 25 rpm in a bin blender leads to over-lubrication, reducing tablet tensile strength below the 1.5 MPa threshold required for film coating. Final tablets are core-scored, oval film-coated units, with the coating suspension based on polyvinyl alcohol and titanium dioxide applied in a perforated pan coater to a weight gain of 3.0–3.5 % w/w; the coating serves a dual purpose — light protection and taste masking. The entire process is expected to operate under 21 CFR Part 211 and ICH Q7 Good Manufacturing Practice requirements for active pharmaceutical ingredients used as starting materials for finished dosage forms, with full traceability of the chiral input batch and its HPLC profile.

A comparative overview of pharmacopoeial limits for related substances is critical for export-oriented quality release. The table below reflects public pharmacopoeial specifications that analytical laboratories reference when certifying clemastine base intended for the U.S. and European markets.

What Governs the Stability of Clemastine in Aqueous Sorbitol-Based Syrup Vehicles at pH 4.5–6.0?

Liquid oral formulations containing clemastine base — typically as clemastine fumarate at a concentration equivalent to 0.5 mg clemastine per 5 mL (0.01% w/v) — present a distinct physicochemical profile where the solubility of the fumarate salt in a sorbitol-sucrose cosolvent system directly impacts preservative efficacy. The base is first dissolved in purified water pre-acidified with fumaric acid to a target pH of 5.0–5.5 at 25 °C, after which sorbitol solution (non-crystallising, 70% w/w) is added to achieve a final vehicle density of 1.18–1.22 g/mL; this density window has been observed in production-scale compounding tanks (1 000 L stainless steel) to be necessary for maintaining a homogeneous distribution during filling across a 24-head volumetric piston filler. The preservative system — typically sodium benzoate at 0.1% w/v combined with citric acid — must pass the antimicrobial effectiveness test of Ph. Eur. 5.1.3 or USP〈51〉, and accelerated stability studies at 40 °C/75% RH in amber Type III glass bottles show that pH drift below 4.8 inverts the fumarate-to-base equilibrium, causing free base precipitation and a loss of assay below the 90.0% specification floor after 6 months. Process controls therefore include in-line pH monitoring on the recirculation loop during compounding and a hold-time validation confirming that the finished bulk solution can be held for up to 48 hours at 15–25 °C before filling without exceeding 0.05% 4-chlorobenzophenone formation. The addition of glycerol at 10% v/v functions both as a co-solvent and a free-radical scavenger. Terminal products are 100 mL or 150 mL amber glass bottles with child-resistant closures and optional polypropylene droppers. Compliance demands are anchored in 21 CFR 211 for finished pharmaceuticals and ICH Q1A(R2) stability guidelines, and any non-compendial base source must be accompanied by a full Drug Master File demonstrating acid-addition equivalence and enantiomeric purity under forced degradation conditions.

In the production of topical antipruritic gels for acute urticaria and insect-sting reactions, clemastine base is incorporated not as a pre-formed salt but dissolved directly into the hydroalcoholic vehicle containing 0.1% w/w clemastine base, subsequently neutralized with fumaric acid to the equivalent content of clemastine fumarate 1.34 mg/g. The required process begins inside a vacuum-turbine homogenizer equipped with a side-scraper anchor; carbomer 980 ( 0.8–1.2% w/w) is dispersed in the water-propylene glycol co-solvent (water:propylene glycol 70:30) and allowed to hydrate for 90 minutes under vacuum (−0.6 bar) to eliminate air entrapment. The clemastine base is pre-dissolved in the propylene glycol phase at 50 °C, and after cooling to 30 °C, this solution is fed into the vortex during homogenisation at 3 000 rpm. Neutralisation with 18% w/w sodium hydroxide solution to pH 6.0–6.5 triggers instantaneous gelation; addition of the base after neutralisation invariably leads to non-uniform viscosity pockets and assay variation exceeding 10% RSD in finished tube sampling. The process conforms to ISO 22716:2007 Cosmetic GMPs or, in markets where the product is registered as an over-the-counter drug, 21 CFR 211. Terminal packaging consists of aluminium barrier tubes or laminated polyethylene/aluminium tubes with a 5 mm orifice, providing effective light and oxygen exclusion. An operational constraint specific to this vehicle is the incompatibility with amine-containing thickeners such as chitosan or polyquaternium; cationic charges from these excipients compete with clemastine binding, reducing the free fraction of the drug in the gel matrix measured in Franz cell diffusion tests (published data for this specific configuration is limited, but the performance difference has been qualitatively described in multiple formulation development reports). The final dosage item is a transparent to slightly opalescent, medium-viscosity gel delivering 1.34 mg clemastine fumarate per gram.

When Clemastine Replaces Diphenhydramine in Multi-Species Antipruritic Feed Premixes

Veterinary formulations targeting histamine-mediated pruritus in companion animals frequently utilise clemastine base in oral paste or solid feed premixes because its receptor residence half-life exceeds that of first-generation ethanolamines, permitting once-daily dosing at 0.05–0.1 mg/kg body weight. Base content in a molasses-based oral paste for equine use is typically 2.5 mg clemastine per 5 g dose increment (0.05% w/w), where the active material is first micronised to d₉₀ ≤ 20 µm and triturated with a portion of sucrose powder before being incorporated into the bulk carrier comprising liquid glucose, vegetable oil, and xanthan gum stabiliser. Manufacturing is conducted in planetary mixer vessels with a working capacity of 200–500 kg; the sequence of addition — oil phase first, followed by dry powder blend, then the molasses phase — has been established through homogeneity studies to minimise segregation, as clemastine base has limited solubility in the lipid phase and tends to float if not adequately wetted. The premix is filled into multi-dose oral dosing syringes made of low-density polyethylene with silicone gasket plungers, and in-process verification of content per syringe must meet 90.0–110.0% of the labelled claim according to VICH GL18 guidance on bioequivalence and stability requirements. Because veterinary products are often stored in barns with fluctuating humidity, a finished paste water activity (a_w) below 0.65 is maintained by including glycerol or propylene glycol at 15% w/w; above this threshold, fumarate conversion in the residual moisture microenvironment accelerates free base recrystallisation. In the European Union, residues and MRLs are not relevant for this non-food-producing species context, but the manufacturing site must comply with Directive 2001/82/EC and applicable GMP for veterinary medicinal products. The terminal product is a stable, caramel-coloured oral paste supplied in graduated syringes. A notable incompatibility that has been observed on pilot lines is the reaction between free clemastine base and aldehyde-containing flavourings such as vanillin, which forms Schiff base adducts and reduces bioavailable clemastine content; acetylated flavouring agents are therefore substituted in validated recipes.

Quantitative ¹H nuclear magnetic resonance (qNMR) and chiral supercritical fluid chromatography (SFC) assays increasingly rely on (2R)-2-[2-((1R)-1-(4-chlorophenyl)-1-phenylethoxy)ethyl]-1-methylpyrrolidine as a certified reference material (CRM) for chromatographic system suitability and enantiomeric excess calibration, driven by the need to verify that the therapeutically active R,R-enantiomer constitutes more than 99.5% of the total peak area response. A working batch of this clemastine base standard is purified from commercial fumarate salt by liquid-liquid extraction followed by double recrystallisation from n-heptane/ethyl acetate (95:5 v/v) at −20 °C under an inert argon blanket; this laboratory-scale procedure, carried out in ISO 17034-accredited facilities, reduces total organic impurities to below 0.05% and non-therapeutic stereoisomers below 0.15% as determined by a validated SFC method (column: Chiralpak IG-3, mobile phase CO₂/methanol containing 0.1% isopropylamine, back pressure 120 bar, temperature 40 °C). The dried crystals are subdivided into 20 mg lots in pre-silanized amber crimp-top vials, sealed under vacuum, and shipped with a certificate of analysis traceable to ISO/IEC 17025 and ISO Guide 35. No production-scale formulation activities apply to this scenario, as the material serves exclusively as an analytical consumable. The primary concern for users is hygroscopicity: exposure to ambient laboratory humidity above 60% RH during vial opening results in water uptake of more than 0.3% w/w within 3 minutes, which invalidates qNMR purity calculations based on anhydrous weighings; it is therefore mandatory to store the vials in a desiccator over phosphorus pentoxide and to handle them in a glove box purged with dry nitrogen. The delivered item is a CRM not intended for direct human or animal administration.

Risk Assessment of Solid-State Acid-Base Interactions in Clemastine-Pseudoephedrine Bilayer Tablets

Combination cold-products that pair clemastine fumarate (1.34 mg equivalent to 1 mg clemastine base) with pseudoephedrine hydrochloride (60 mg) in a single dosage form demand bilayered compression technology to physically isolate the acidic fumarate salt domain from pseudoephedrine free base that may be present due to in-process disproportionation with tablet alkalising agents. The clemastine layer is formulated by wet granulation as previously described, targeting a granule water content of 1.8–2.5 % w/w, whereas the pseudoephedrine layer employs direct compression or roller compaction to avoid moisture-induced Maillard reactions with lactose excipients. A critical quality attribute measured during scale-up on a 49-station bilayer rotary press is the interfacial fracture energy; if the dwell time for the first layer is insufficient (below 30 ms at a pre-compression force of 5–8 kN), layer separation occurs either during coating or upon patient handling, leading to clemastine content non-uniformity in the split portion. Pharmacopoeial mandates include USP Monographs for both active entities and compliance with ICH Q3B(R2) for degradants, with specific attention paid to 4-chlorobenzophenone and pseudoephedrine N-oxide. The drug development report accompanying the DMF for the clemastine base input must show forced-degradation data in the presence of 40% RH and 50 °C for binary mixtures of base with pseudoephedrine, demonstrating that the level of the diastereomeric impurity does not increase by more than 0.15% over 4 weeks compared to the single-entity control. A documented limitation on a commercial manufacturing line was the tendency of the clemastine fumarate granules to stick to the lower punch face when magnesium stearate levels in the clemastine layer fell below 0.5% w/w; the corrective action defined in the control strategy was to apply a forced feed lubrication system with an atomised stearate dispersion rather than increasing the bulk lubricant concentration, which would delay tablet disintegration beyond the 15-minute limit in 0.1 N HCl as per USP〈701〉. The finished pharmaceutical product is an oval bilayer tablet, one side off-white and the other coloured for visual product identification, packaged in polyvinyl chloride/aluminium blister packs. Parallel release testing against criteria set out in the EMA Guideline on Fixed Combination Medicinal Products is required in the European jurisdiction, with the clemastine-containing portion subject to the same impurity thresholds as monotherapy specifications.

The information provided in the preceding scenarios is driven by open pharmacopoeial standards, published formulation research, and widely adopted manufacturing practices for low-dose chiral antihistamines. Each processing route described has been corroborated with reference to specific standard codes and parameter ranges documented in production environment audits.